Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade Release 10.2

21 Jan 2016 08:29

RNS Number : 5678M
Sopheon PLC
21 January 2016
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Accolade Release 10.2 Increases Innovation Project Velocity

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, announces today the latest version of its Accolade Enterprise Innovation Management solution.

Accelerated innovation velocity: Time is money, and creating new technologies and bringing new products to market more quickly means increased profits and revenues. Intelligent automation and smart workflows in Accolade 10.2 reduce the amount of manual intervention required for innovation processes to keep moving forward at pace, and enhance the flow of communication and collaboration across even highly dispersed work teams. Companies can use these capabilities to accelerate project velocity and time to market, helping them move with greater speed and focus towards the next innovation milestone.

A Sopheon customer-a multi-billion dollar chemical company and early reviewer of Accolade release 10.2-plans to significantly reduce time-lags and human error in the decision-making process by having their Accolade system automatically move projects to the next stage in the development cycle. These migrations will be triggered when pre-defined key performance indicators are met and/or when all relevant stakeholders have given approval in Accolade.

More focused and efficient user experience: This release is another step forward in raising the industry standard on user engagement in the innovation process by bringing critical documents, information and data into core innovation workflows, enabling people to complete their work more efficiently and with less effort.

Don Sarno, Chief Operating Officer at Sopheon says, "CEOs understand that speed-to-market and agility are competencies critical to surviving in the new norm of competitive markets. With Accolade release 10.2, we continue to provide a tight alignment and personal connection between team member activities and company value, in addition to reducing wasted cycles from the top of the organization to the front line."

 

Sopheon® and Accolade® are trademarks of Sopheon.

 

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1276 919 560

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Ed Frisby / Carl Holmes (corporate finance)

Mia Gardener (corporate broking)

finnCap

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKDDBFBKKFDB
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.